Recent research have focused on the convergence of GLP|GIP|GCGR stimulant therapies and DA signaling. While GLP stimulators are widely employed for treating type 2 diabetes, their emerging effects on reward circuits, https://lilianjyup602751.dm-blog.com/41750633/novel-gcgr-activators-and-da-adjustment-a-contextual-examination